Cyclic variations in coronary blood flow (CFVs) in dogs with experimental coronary artery stenosis and endothelial injury appear to result primarily from the aggregation of platelets at the site of stenosis followed by dislodgement and distal embolization. Using this canine model, we tested the hypotheses: (a) that thrombin is an important mediator of CFVs in dogs with coronary stenoses and endothelial injury; (b) that inhibition of thrombin with heparin, or MCI-9038, a selective thrombin inhibitor, abolishes CFVs in this model; and (c) that abolition of CFVs by thrombin inhibition is time dependent. CFVs, produced in open-chest dogs by placing a flow-reducing plastic constrictor around the left anterior coronary artery, were monitored for either 30 min (group I) or 3 h (group II) before treatment with either heparin or 4-methyl-14N'-+(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl 
Introduction
Platelet-mediated obstruction of stenotic coronary arteries with damaged endothelium may be an important factor in certain occlusive coronary disease states (1) (2) (3) (4) (5) (6) . Using a welldefined canine model of in vivo platelet aggregation described originally by Folts et al. (7) , we have shown that TXA2 (8, 9) and serotonin (10) (11) (12) are important mediators of platelet aggregation and that the inhibition of serotonin receptor activation (10) (11) (12) or the inhibition of TXA2 synthesis (8) Receivedfor publication 1 July 1988 and in revisedform 28 Thrombin is the central bioregulatory enzyme in hemostasis (13) . It is a potent activator of platelets either alone or in synergism with other agents (14) . It is responsible for the conversion of fibrinogen to fibrin and for the activation of coagulation Factors V, VIII, and XIII (13) . Thrombin may interact directly with the vessel wall, causing vasoconstriction (15, 16) and may mediate leukocyte adherence (17) . Mathematical models have predicted that thrombin, but not ADP or TXA2, is present in sufficient concentration at the site ofendovascular injury to initiate the first wave of platelet aggregation (18) . It was our objective to test the effect of thrombin inhibition on the occurrence of platelet-dependent CFVs in dogs with coronary artery stenosis and endothelial injury. It is possible to inhibit thrombin either indirectly with heparin or directly with a synthetic thrombin inhibitor. The primary action of heparin is to accelerate the activity of the circulating anticoagulant, antithrombin III (ATIII) (19) . Heparin may also have thrombin inhibitory activity independent of ATIII (20) . MCI-9038 (4-methyl-I -[N2-[(3-methyl-1,2,3,4-tetrahydro- 8-quinolinyl) sulfonyl]-L-arginyl]-2-piperidinecarboxylic acid) (obtained from Mitsubishi Chemical Industries, Tokyo, Japan) is a potent, highly selective inhibitor of thrombin whose effect is independent of ATIII (21, 22) . We relied upon the ability of heparin or MCI-9038 to inhibit thrombin to test the hypotheses: (a) that thrombin is an important mediator of platelet aggregation and resultant CFVs in a canine model ofcoronary stenosis and endothelial injury; (b) that inhibition ofthrombin abolishes CFVs in this model; and (c) the abolition ofCFVs by thrombin inhibition with heparin or MCI-9038 is time dependent.
Methods
Surgical preparation. 39 mongrel dogs of either sex, weighing kg, were anesthetized with 30 mg/kg sodium pentobarbital and ventilated with a mechanical respirator (Harvard Apparatus Co., Natick, MA). A heating pad was used to maintain body temperature at 38°C. Carotid arterial and jugular venous catheters were inserted through a neck incision. A left fifth intercostal space thoracotomy was made and the heart was suspended in a pericardial cradle. A 2-cm segment ofthe left anterior descending coronary artery was gently isolated. An ultrasonic flow probe (Doppler; Hartley Instruments, Houston, TX) (23) was placed around the proximal segment of the coronary artery to measure phasic and mean coronary blood flow. After a 30-min stabilization period, control values for heart rates, blood pressures, and phasic and mean coronary blood flows were recorded on an eight-channel recorder (model 7758; Hewlett-Packard, Palo Alto, CA). After injuring the endothelium by gently squeezing the artery with a cushioned forceps, a hard cylindrical constrictor was placed around the artery at the site of injury to reduce phasic coronary blood flow -50%. CFVs were allowed to develop and continuously monitored according to the following experimental protocol.
Control group. Five dogs were instrumented as previously described. CFVs were allowed to develop and monitored continuously for 5 h. Placebo injections of normal saline (50 ml) were administered every 30 min. Record was made of the heart rates, blood pressures, frequency of CFVs, and the severity of CFVs as indicated by the nadir coronary blood flow.
Experimental groups. To assess the importance oftime dependence on thrombin mediation of CFVs, two groups of dogs were defined by the duration of CFVs before thrombin inhibition. In group I (n = 25), CFVs were monitored for 30 min before treatment with either heparin sodium (24) (group IA) (n = 18) from beef lung (Upjohn Pharmaceuticals, Kalamazoo, MI) or MCI-9038 (group IB) (n = 7). In group II (n = 14), CFVs were monitored for 3 h before treatment with either heparin (group IIA) (n = 7) or MCI-9038 (group IIB) (n = 7). The initial bolus doses of heparin (200 USP units/kg i.v.) or MCI-9038 (0.5 mg/kg i.v.) were repeated as needed to prolong the activated clotting time (ACT) to 350-400 s (control = 90-100 s). The ACT was measured with an automated blood-coagulation timing device (Hemochron; International Technidyne Corp., Edison, NJ). Additional doses ofeither heparin or MCI-9038 were administered by either intravenous infusion or bolus to maintain a stable level of anticoagulation (ACT > 350 s) throughout the remainder ofthe experiment. The heart rates and blood pressures were recorded and the frequency and severity of CFVs were determined before and after treatment with heparin or MCI-9038. The subsequent protocol for each dog depended upon the response to the initial treatment with heparin or MCI-9038.
CFVs Platelet aggregation. The effect of MCI-9038 or heparin on the aggregation of canine platelets in response to a panel of agonists was examined in a dual-channel aggregometer (Chronolog Instruments, Havertown, PA). Platelet-rich plasma (PRP) was prepared from whole blood collected into acid-citrate-dextrose (6:1) followed by centrifugation at 250 g for 20 min at 37°C as described by Aster et al. (28) . Platelet-poor plasma (PPP) was obtained after centrifugation of platelet-rich plasma at 2,000 g for 10 min. The platelet count was adjusted to 300,000/ml. Washed canine platelets were prepared according to the method of Ardlie et al. (29) . After centrifugation and washing twice, the platelets were suspended in Tyrode's solution (30) containing 2 mM calcium, 1 mM magnesium, and 0.35% albumin. Blood samples were obtained during the control period before constrictor placement, after 30 min of CFVs, and after 3 h of CFVs.
In each case, a 450-Ml sample of either PRP or washed platelet suspension was transferred to a l-ml glass cuvette and stirred at 1,100 rpm for a 2-min equilibration period at 37°C. The agonists and range of final concentrations were ADP (Sigma Chemical Co., St. Louis, MO), 1-10 WM; bovine collagen (Hormon-Chemie, Munich, West Germany), 1-10 ug/ml; human thrombin, (Helena Laboratories, Beaumont, TX), 0.3-0.6 U/ml; and U46619, a synthetic TXA2 analogue (Upjohn Pharmaceuticals), [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 
Results

Hemodynamics
The hemodynamic record from control, group I, and group II dogs is listed in Table I . The heart rates, blood pressures, and frequency and severity of CFVs in the control dogs were stable during a 5 h period of observation (Fig. 1) . Placebo injections of normal saline had no effect on hemodynamics or coronary blood flow.
Effect oftreatment Group I. After 30 min of CFVs, treatment with heparin (average initial dose 444±71 U/kg; range, 200 to 1,000 U/kg) abolished CFVs in 12 of 18 dogs (66%) (Fig. 2) , and treatment with MCI-9038 (average initial dose 1.96±0.86 mg/kg; range, 0.5 to 7.0 mg/kg) abolished CFVs in 5 of 7 dogs (71%) (66 vs. 71 %, P = NS) (Figs. 3 and 4 ). There was a significant decrease in both the frequency and severity of cyclic flow variations after treatment with either heparin or MCI-9038 (Table 1 ). There were no significant hemodynamic effects related to the administration of either heparin or MCI-9038.
In five of six group I dogs observed for 4 h after cyclic flow variations were initially abolished by the administration of 129±11  128±13  127±9  125±7  123±7   122±7   136±4  132±4  127±4  122±4   142±9   136±11  131±8  139±19   152±7  143±9  133±9  127±6*  127±7*  135±9   144±8  143±8  136±8  136±8  134±7  139±7   111±8  107±8  107±6  113±4  120±6  113±6  112±8   116±4  113±4  114±3  114±3   131±9  133±8  129±9  128±9   122±4  115±8  112±4  113±4  116±4  114±5   132±4   135±4 §   128±2 §  132±3 §  135±2 §  139±2 §   90±9  87±8  88±6  86±7  89±6  80±7  84±7   94±4  94±4  92±3  90±3   110±8  108±8  105±9  101±8   100±3  96±7  95±4  91±4  91±5  89±4   98±6  104±4  100±4  101±5   101±4   97±5   100   46±7*  99±7  113±7  116±8  113±8 (Fig. 4) . The treatment groups were equivalent during the time period before treatment with regard to the degree of stenosis (Table I) , platelet count, and hematocrit (Table II) . The doses of heparin or MCI-9038 were equivalent in all treatment groups (Figs. 6 and 7) . The level of anticoagulation as measured by the ACT and the aPTT were equivalent in all treatment groups (Table II) . In two dogs, we measured the blood level of MCI-9038 or heparin using the aPTT. The blood level of MCI-9038 at an ACT > 350 was 0.25-2.5 gM and the heparin level at an ACT > 350 s was 1.0-10 U/ml. There was no significant change in platelet count or hematocrit during the course of observation. Systolic blood pressures were slightly higher in group IIB than in other groups, but this does not appear to have affected the overall results (Table I) Ketanserin administration was associated with a modest decrease in arterial blood pressure, a slight decrease in the peak phasic coronary blood flow, and a marked increase in mean nadir coronary blood flow (Table III) .
Platelet aggregation
The effects of MCI-9038 on platelet aggregation are recorded in Table IV . In PRP, MCI-9038 at concentrations as high as 2,000 AM did not inhibit platelet aggregation in response to ADP (5 MM) or U46619, the TX analogue (1 gg/ml). MCI-9038 inhibited thrombin-induced (0.6 MuM) platelet aggregation in a dose-dependent manner with an IC50 = 0.2,uM AORTIC 20 _ .0
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Discussion
The data from the current study support the contention that thrombin may be an important mediator of platelet aggregation in vivo and that the role of thrombin is highly time dependent. CFVs were abolished in most dogs after short periods (30 min) of CFVs, but not after longer time periods (3 h ). In the model that we have used, CFVs appear to result from the aggregation of platelets at the site of experimental coronary stenosis and subsequent dislodgement and embolization (6) (7) (8) 12) . The abolition of CFVs is therefore a relative measure of the inhibition ofin vivo platelet aggregation. The level ofanticoagulation as measured by the prolongation of the ACT and the aPTT was used as an indirect measurement ofthe degree of inhibition of thrombin activity. Thus, it is probable that the inhibitory effect of heparin or MCI-9038 on the development of CFVs in this model was a result of the inhibition of platelet activation by thrombin. The Folts animal model (7) is a well-established model of the development of cyclic coronary blood flow reductions that are believed to result primarily from the accumulation of obstructive platelet aggregates at the site ofa man-made coronary artery stenosis and induced endothelial injury, and subsequent embolization (6) (7) (8) 12) . In the present study and in previous reports (8), we and others (7), have demonstrated the presence of occlusive platelet-rich aggregates at the site of the coronary constrictor in arteries obtained at the nadir of coronary blood flow. We have also found that in cases of severe thrombocytopenia (< 30,000), CFVs do not develop despite severe coronary stenoses and endothelial injury (unpublished observations). It has also been shown that inhibition of platelet adhe- Before SQ29548 (n = 1 1) 131±6 131±5 100±4 107±13 20±5 140±17 22±7 4.4±1 After SQ29548 (n = 11) 130±6 128±5 94±4* 105±13 71±12* 128±17 86±13* 1.1±0.6* Before ketans (in combination with SQ29548) (n = 4) 128±10 126±11 101±10 118±29 29±6 147±39 40±9 3±1 After ketans (in combination with SQ29548) (n = 4) 128±13 104±9* 81±8* 78±20* 78±20 77±12 77±12* 0* Ketans, ketanserin, a serotonin receptor antagonist; SQ29548, TXA2/PGH2 receptor antagonist. n = 11; * P < 0.05. For other abbreviations, see Table I. sion with a MAb to the glycoprotein IIb/IIIa receptor prevents CFVs in most cases (36) . Finally, the finding that inhibition of serotonin receptor activation (10) (11) (12) or the inhibition of TXA2 synthesis (8) or receptor activation (9) 
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=~A lthough the occurrence of CFVs in this model appears to be primarily a platelet-dependent phenomenon, we do not discount the importance of other factors that may contribute to the reduction in coronary blood flow. We have shown that enhanced vasoconstriction at the site ofplatelet accumulation, apparently due to the local release of platelet-derived vasoactive substances, including serotonin and TXA2, may contribute to the reduction in coronary blood flow in this model (37) . In addition, leukocytes and other mediators of inflammation and the generation of fibrin clot may also be involved.
MCI-9038 is the most potent and selective member of a family of recently synthesized thrombin inhibitors (21) . In other animal models, it has been demonstrated that its antithrombotic effect is independent of ATIII (38) . In humans, it has been used for anticoagulation during cardiopulmonary bypass (39) and hemodialysis (40) and for the treatment of disseminated intravascular coagulation (39) . Its use has not been associated with platelet activation or thrombocytopenia (41) and MCI-9038 does not inhibit plasmin to any significant degree (21) . In a rat model of cerebral microcirculation thromboembolism, MCI-9038 was found to inhibit the formation of occlusive platelet aggregates (42).
MCI-9038 is a substituted arginine derivative with three binding regions that correspond to (a) a positively charged guanidino group, (b) an aromatic N2-substituent, and (c) a hydrophobic carboxamide portion (22) . The specificity of MCI-9038 for thrombin has been shown to be dependent on a stereospecific interaction between the carboxamide substituent of MCI-9038 and a hydrophobic binding pocket on thrombin (22) . The doses used in this experiment resulted in circulating blood levels of MCI-9038 (0.25-2.5 ,uM) well within the thrombin sensitive range, and it is unlikely that the inhibition of other proteases was responsible for the effects observed.
Evidence from this study confirms the ability of MCI-9038 to inhibit thrombin. MCI-9038 prolonged the standard Heparin is a heterogeneous, polydisperse glycosoaminoglycan with a molecular mass range from 3,000 to 30,000 D (43) . Commercial preparations are usually produced by extraction from porcine intestinal mucosa or bovine lung. The principal mode of action of heparin is thought to be the enhancement of the antiprotease activity of ATIII (44) . The effect of the antithrombin/heparin system may be mediated through either (a) the inhibition of thrombin or (b) the inhibition of the catalysis of prothrombin to thrombin (45) . The inhibition of thrombin not only blocks the conversion of fibrinogen to fibrin monomer, but also prevents the thrombindependent activation of factor V (44) . Activated factor V (Va) combines with Factor Xa on the platelet surface membrane to form the prothrombinase complex, which catalyzes the conversion of prothrombin to thrombin (45) . The prompt inhibition of the activation of Factor V effectively blocks the coagulation sequence before the generation of additional thrombin.
Heparin may also have an important inhibitor effect on platelet function that is independent ofATIII (46) . Heparin, in the absence of ATIII, has been shown to inhibit thrombin-induced aggregation ofwashed rabbit platelets (47) and to inhibit thrombin-stimulated generation of platelet factor Va (48). Heparin may also induce a functional platelet defect at the level of the platelet membrane (49) . The data from this study confirm the ability of heparin, in the absence of ATIII, to inhibit the activation of platelets by thrombin. Heparin also inhibited the aggregation of both washed platelets and PRP in response to collagen. The mechanism ofthis effect is not clear. An RIA for the detection of circulating free thrombin has been described, but thrombin is ordinarily not detectable in plasma due primarily to its rapid inactivation by ATIII (50) (51) (52) . A quantitative estimation ofthrombin activity can be derived from the presence of thrombin-antithrombin complexes (49, 51) . In comparison to the individual molecules, the thrombin-antithrombin complex possesses unique antigenic determinants that can be detected by immunoassay (49, 50) , and it has a higher molecular weight on gel electrophoresis (42) . In this experiment, we were unable to detect free thromThrombin Mediates Platelet Aggregation In Vivo 25 2 i bin in either venous or coronary arterial blood until the addition of exogenous thromboplastin. Although thrombin appears to play an important role in mediating the development of cyclic flow variations, the effect seems localized to the specific area of arterial injury.
Although differing in their structure and mechanisms of action, heparin and MCI-9038 share the ability to inhibit thrombin (19, 21) . Heparin acts primarily indirectly by enhancing the effect of ATIII (19) , whereas MCI-9038 forms a 1:1 stoichiometric complex with thrombin that prevents its proteolytic and platelet-stimulating activities (21) . That either heparin or MCI-9038 abolished CFVs after short periods of CFVs argues in favor of the conclusion that the inhibition of thrombin results in inhibition of platelet aggregation in this model. It is important to note that both heparin and MCI-9038 may have actions other than the inhibition of thrombin and that these actions may have played a role in the results observed in this experiment.
The explanation for the success of abolition of CFVs with either heparin or MCI-9038 after short but not prolonged periods of CFVs is not clear. The ability of either heparin or MCI-9038 to abolish CFVs after short but not prolonged time periods suggests that either thrombin inhibition is more difficult after long periods of CFVs and/or thrombin plays a less important role in mediating platelet aggregation after longer time intervals. Local accumulations of thrombin within the thrombus may be relatively resistant to inhibition by circulating inhibitors. It is also possible that other mediators ofplatelet activation, including collagen, TXA2 and ADP, achieve sufficient local concentration to mediate platelet aggregation even in the presence of thrombin inhibitors (18) .
The results from this study support our previous findings that TXA2 and serotonin are important mediators of platelet aggregation and resultant CFVs in dogs with coronary artery stenosis and endothelial injury (8) (9) (10) (11) (12) . The TXA2 receptor antagonist, SQ29548, and/or the serotonin receptor antagonist, ketanserin, abolished CFVs in every case in which thrombin inhibition with heparin or MCI-9038 failed to do so. The efficacy of treatment with SQ29548 and ketanserin was not related to the duration of CFVs before treatment.
In conclusion, the results from this study support the following hypotheses: (a) thrombin appears to be an important mediator of CFVs in a canine model of coronary artery stenosis and endothelial injury and (b) the inhibition of thrombin, with either MCI-9038, or heparin, abolishes CFVs in most dogs after short but not prolonged periods of CFVs. These findings suggest that either thrombin plays a less important role in mediating platelet activation after prolonged periods of CFVs and/or that the inhibition of thrombin at the site of endovascular injury with heparin or MCI-9038 is more difficult at later times.
